Drug intelligence / Profile preview

BG505

Development stage: Unknown
Lead developer: International AIDS Vaccine Initiative
Modality: Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

BG505 is an investigational HIV vaccine candidate based on the HIV-1 envelope glycoprotein (Env) trimer. It is designed to induce broadly neutralizing antibodies (bnAbs) by mimicking the native-like Env trimer, presenting conserved epitopes to the immune system. Various forms, including soluble, membrane-bound, and SOSIP-stabilized versions (e.g., BG505 MD39.3, BG505 SOSIP.664 gp140, BG505 SOSIP.GT1.1 gp140), are being evaluated, often in combination with adjuvants such as TLR agonists (e.g., 3M-052-AF, 3M-052-SE) and alum, to enhance the immune response against HIV infections.

Targets

BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)

Beyond the preview

Go deeper on BG505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG505.

Explore the full profile